Background: Detailed information regarding the clinical efficacy of radiotherapy (RT) for primary tumor in patients with unresectable pancreatic neuroendocrine tumors (pNETs) is unknown. We therefore performed a retrospective study to evaluate the efficacy and safety of RT for primary pancreatic tumors in patients with pNETs. Methods: We investigated 11 patients with pNETs who received RT to the primary site between January 1997 and June 2015. Seven patients had Grade 2 neuroendocrine tumors (NET-G2) and four had neuroendocrine carcinoma (NEC) according to the 2010 WHO histopathological classification. Results: The tumor response and control rates were 27.2% and 100%, respectively (3: partial response, 8: stable disease). Among patients with NET-G2 tumors, the response rate was 28.5% (2/7 patients) and symptomatic improvement was noted in 33.3% of the patients (1/3 patients). The response rate for patients with NEC were 25% (1/4), one NEC patients with symptoms exhibited symptomatic improvement. The median overall survival and median progression-free survival were 35.9 months and 5.5 months, respectively. Grade 3 diarrhea as an acute toxicity and Grade 3 gastrointestinal hemorrhage as a late toxicity were observed. Conclusions: RT to the primary cancer site in patients with pNETs was an effective modality for local disease control and the treated patients had good outcomes. If metastatic tumors are under control, RT to the primary site may be beneficial for patients with pNETs.
Introduction
Pancreatic neuroendocrine tumors (pNETs) are tumors derived from neuroendocrine cells in the pancreas. They are comparatively rare, accounting for only~3% of all pancreatic tumors (1) . In Japan, the prevalence was estimated to be 2.69/100 000, with an annual onset incidence of 1.27/100 000 in 2010 (2) . In 2010, the World Health Organization (WHO) classified pNETs as neuroendocrine tumors Grade 1 (NET-G1), neuroendocrine tumors Grade 2 (NET-G2) or neuroendocrine carcinoma (NEC) on the basis of the Ki-67 index and mitotic count (3) . Currently, treatment based on this histopathological classification is considered important.
Surgical resection is the only potentially curative treatment for pNETs (4) (5) (6) (7) . The prognosis of pNETs other than NECs is relatively good (8) . Therefore, not only surgical resection but multimodality treatment including radiotherapy (RT) is more likely to help improve outcomes.
RT is thought to be an effective modality to relieve the clinical symptoms of brain or bone metastases of pNETs (4, 9, 10) and is commonly used in clinical practice. However, few studies have addressed the irradiation of primary pancreatic tumors, and there are not any reports that used a pathological classification based on the WHO 2010 classification. In particular, when metastasis to other organs is controlled by local treatment such as TACE, and it is a case of unresectable local advanced cancer without distant metastasis, RT for primary pancreatic tumors can become an important treatment strategy to control primary tumor growth and to manage its related symptoms. We therefore performed a retrospective study of the efficacy and safety of RT to the primary site in patients with pNETs.
Patients and methods
A total of 11 patients who had undergone RT for primary pancreatic tumors out of 100 who had received a histopathological diagnosis of pNETs and undergone treatment at the National Cancer Center Hospital (NCCH) between January 1997 and June 2015 were enrolled in the study. RT for pNETs is mainly considered if the disease is symptomatic or the standard treatment at that time were not effective. The tumors were classified histopathologically according to the 2010 WHO classification as NET-G1, NET-G2 or NEC. Patients who were treated before 2010 were pathologically reevaluated and re-classified in accordance with the 2010 WHO classification.
We used the medical records of these 11 patients to investigate their sex, age, Union of International Cancer Control (UICC) stage, location of pancreatic tumor, location of metastases, histological type, presence or absence of hormone production, symptoms, family history of pancreatic tumor or multiple endocrine neoplasia (MEN), and treatment prior to RT. We also investigated the type of RT used, dose per fraction, number of fractions, number of sessions, and use of combination chemotherapy. Based on these parameters, we used Kaplan-Meier curves to investigate overall survival (OS), defined as the time from the start of RT until death, and progression-free survival (PFS), defined as the time from the start of RT until the progression in primary site, liver metastasis, or other metastases. Overall response evaluation was performed in accordance with the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, measured by computed tomography (CT) or magnetic resonance imaging (MRI). Symptomatic relief was investigated by a close examination of medical records, from which symptoms such as pain, hypertension, nausea and diarrhea were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, and an improvement in an adverse event by one or more grades was counted as symptomatic relief. Adverse events were defined as acute toxicity if they occurred within 6 months of the start of RT, and as late complications, if they occurred after this point, and were also evaluated in terms of the CTCAE version 4.0. The data analysis was performed in May 2016.
The level of statistical significance was set as P < 0.05 (twotailed), and differences in survival were tested by using a log-rank test, with JMP Pro 12.0.2 (SAS Institute, Inc., Cary, NC, USA) used for statistical analysis. This retrospective, non-invasive study was approved by the Ethics Committee of the NCCH. All values were expressed as medians. Table 1 shows the characteristics of the 11 patients before the start of RT. There were five men and six women, with a median age of 50 years (range 37-76 years). Their performance status (PS) was good (score, 0 or 1) in all but one patient. No patient had a family history of MEN or pancreatic tumor. The stage at the start of RT was Stage III (locally advanced disease) in three patients and Stage IV (metastasis to the liver and other regions) in the other patients. Seven patients had NET-G2 tumors and four had NECs according to the 2010 WHO histopathological classification. Four were cases of functioning pNETs (two cases of VIPoma and one case each of gastrinoma and ACTH-producing tumors) and seven were cases of nonfunctioning pNETs; three of the patients with functioning pNETs and one with a nonfunctioning pNET exhibited tumorrelated symptoms such as hormonal symptoms and pain prior to RT. The location of the primary tumor was the head of the pancreas in five patients, and the median longest diameter was 46 mm (range 29-95 mm). One patient underwent no other treatment prior to RT, and the remaining 10 had received previous treatment such as chemotherapy or TACE for liver metastases; however, no patient had undergone surgical resection. The median time from initial treatment for pNET to the start of RT was 5.4 months (range 0-38.1 months).
Results

Patient characteristics
RT irradiation methods
RT was performed for improving local tumor control in all patients and for relieving symptoms in the four symptomatic patients. Table 1 shows the type of RT performed for each patient. RT was delivered using X-ray to 10 patients (via three-dimensional conformal radiation therapy (3DCRT) in nine patients and intensity modulated radiotherapy (IMRT) in one patient) and via proton therapy in one patient. 3DCRT treatment was performed at 50 Gy (25 fractions) to 54 Gy (30 fractions); IMRT, at 60 Gy (30 fractions); and proton treatment, at 54 GyE (30 fractions).
Combination chemotherapy was administered to two patients, with Patient 3 receiving therapy with S-1 and Patient 6, with 5-FU. In Patient 2, octreotide was administered throughout all courses as well as during the period of RT administration.
We irradiated only the site of the primary pancreatic tumor, except in one patient (Patient 6) who had locally advanced cancer in the body of the pancreas. Patient 6 received RT to not only the primary pancreatic tumor but also prophylactically to the site around the celiac artery and superior mesenteric artery. No cases received RT to the para-aortic lymph nodes prophylactically.
Response to treatment Table 1 shows the response to treatment in the 11 cases. In terms of shrinkage of the primary tumor, a partial response (PR) was achieved in three patients and stable disease (SD) in eight, yielding a response rate of 27.2% (3/11 patients) and a tumor control rate of 100% (11/11 patients). In other words, none of the patients were considered to have growth of the primary pancreatic tumor at the time of analysis. In Patient 2, the longest diameter of the tumor decreased from 78 mm to 38 mm (Fig. 1) . Among the four patients who were symptomatic prior to RT, symptomatic improvement in terms of improved diarrhea, hyperpigmentation and lowered blood pressure was evident in two patients (50%). Octreotide through all courses was administered to Patient 2, but improvement of the diarrhea from Grade 4 to Grade 2 only occurred 3 months after RT. Also, in Patient 8, ACTH levels was 205.5 pg/ml under Metyrapone (1500mg/day) before RT, and it decreased to 136.2 pg/ml under (750mg/day) after 6 months of RT. Patients with NET-G2 tumors had a response rate of 28.5% (2/7 patients) and 1 out of 3 patients with symptoms before treatment exhibited symptomatic improvement (33.3%). The response rate for patients with NEC were 25% (1/4), one NEC patients with symptoms exhibited symptomatic improvement such as hypertension and hyperpigmentation despite reducing the dose of Metyrapone.
At the time of analysis, progression had occurred in seven of the 11 patients with pNETs. This progression included metastases to other organs in three patients (metastases to the liver in two cases and to the brain in one case), increased pleural effusion or ascites in two patients, peritoneal dissemination in two patient, and lymph node enlargement in one patient. The median PFS was 5.5 months (95% confidence interval [CI]: 3.7-28.2 months), and the 1-year, 2-year and 3-year PFS rates were 45.4%, 24.2% and 12.1%, respectively. Median PFS for those with NET-G2 tumors and NECs was 5.5 months (95% CI: 3.0-28.2 months) and 12.9 months (95% CI: 3.7-21.9 months), respectively.
In terms of local response, the primary pancreatic tumor in 2 of 6 patients who had died at the time of analysis continued to shrink and in three it was unchanged. In the sixth case, Patient 3, the tumor initially shrank after radiotherapy but then grew slightly (from 29 to 21 to 24 mm), and the patient was assessed as having SD.
Among the five surviving patients, the tumor continued to shrink only in Patient 6 and remained unchanged in three patients. In Patient 8, the tumor initially shrank after radiotherapy but then grew (from 95 to 65 to 70 mm), although the patient was assessed as having SD. These results showed that no obvious growth of the primary pancreatic tumor was observed in any patient at the time of analysis, and local control was therefore good.
At the time of analysis, 6 of the 11 patients had died; in all patients, the cause of death was metastasis to other organs or exacerbated hormonal symptoms. The median OS was 35.9 months (95% CI: 9.04 months-not reached), and the 1-year, 3-year and 5-year survival rates were 72.7%, 40.4% and 20.2%, respectively. The median OS was 55.2 months (95% CI: 4.24 months-not reached) for patients with NET-G2 tumors and 35.9 months (95% CI: 9.99-35.9 months) for patients with NECs.
Adverse events
RT was completed for all patients. In terms of acute adverse events, two patients experienced serious complications. Patient 5, who underwent RT for a VIPoma, developed Grade 3 diarrhea and required hospitalization for hypokalemia. Patient 7, who suffered from gastrinoma, developed frequent vomiting after RT and required hospitalization. Other adverse events included the gastrointestinal symptoms of vomiting, nausea, and diarrhea as well as mild bone marrow suppression; however, these were successfully managed with supportive therapy, and the tolerability of RT was generally good. Late toxicity developed in Patient 6 in the form of gastrointestinal hemorrhage from local gastric antral vascular ectasia 7 months after the end of treatment; however, this improved after endoscopic hemostasis was performed. No deaths were associated with RT. Figure 2 shows the overall course of treatment for all 11 patients. One patient, Patient 4, underwent distal pancreatectomy after irradiation and underwent pancreaticoduodenectomy as the second operation because the margin was positive. Only one patient, Patient 11, underwent RT without any previous treatment; in the remaining patients, RT was administered after they had received chemotherapy or local therapy with a procedure such as TACE. After undergoing RT, two patients were not found to require any further treatment, and Patient 6 remained progression-free after 9 years. Three patients died within 2 years because of metastasis to other organs and/or endocrine symptoms such as diarrhea. Among the long-term (>2 years) survivors, the primary pancreatic tumor was controlled. After RT, there was no the metastases to other organs, or the metastatic lesions showed a good response to treatment.
Clinical course
Discussion
Lymph node or liver metastases are already present when many pNETs are diagnosed, with distant metastasis reportedly present at the time of diagnosis in~40% of cases (11, 12) . For liver metastases, local treatment such as TACE, RFA or surgical resection is chosen. Controlling liver metastases is important for improving quality of life (QOL) and the 5-year survival rate (13, 14) , and local debulking of liver metastases might contribute to relieving symptoms and prolonging survival.
The pancreatic tumor itself, however, is difficult to treat by local therapies such as TACE and RFA because of the potential risk of pancreatitis and the leakage of pancreatic juice, and there have been few reports of treatment methods other than surgical therapy. Debulking surgery is currently a matter of debate; however, Pederzoli et al. reported that debulking might control symptoms and improve survival outcomes (15) , and it is possible that tumor debulking at the site of the primary pancreatic tumor might improve QOL and prolong survival.
A summary of published studies with pancreatobiliary-NETs patients treated with RT are shown in Table 2 . Contessa et al. used RT to treat 14 patients with pNETs and reported that the median OS for patients in whom the primary cancer was treated was 2.1 years (95% CI: 1.7-5.4 years). (16). Saif et al. used RT in combination with capecitabine or 5-FU to treat three patients with locally advanced pNET, and found that local control was good in all patients, symptoms improved, and the treatment was tolerable. Recurrence was noted 12-27 months after treatment (17). Lee et al. used RT to treat pancreatic tumors in three patients with pNETs. In those patients, etoposide and carboplatin were also used, and the OS was 2-60 months. One patient underwent surgery after RT and did not develop recurrence, and in the other two patients, the primary tumor was assessed as SD or PR. Two patients died of liver or lung metastasis after treatment. They concluded that tumors might respond to RT and local control might be achievable (18) . Strosberg et al. used chemoradiotherapy with 5-FU or capecitabine or alternatively with streptozotocin and doxorubicin to treat six patients with locally advanced pNETs, and found that the response rate was 80% (19) . In a case report, one patient maintained a CR for 17 months after irradiation of a locally advanced pNET (20) . The common factors in all these reports are that pNETs exhibit comparatively good sensitivity to RT, offering the prospect of symptomatic improvement and tumor shrinkage or the control of growth, and that this treatment is tolerable. Although a few studies of RT have been performed, as mentioned above, we were unable to identify any reports that used a pathological classification based on the WHO 2010 classification. Because the NETs investigated in previous studies might have included a mixture of histological groups with different characteristics, the results must be evaluated with caution.
In this study, the disease control rate was 100%, and the response rate was 27.2% (3/11), a good local response to RT consistent with those described in previous reports. When the tumors were classified as NET-G2 or NEC, their respective response rates were 28.5% (2/7) and 25.0% (1/4). Symptomatic relief was evident in 50% of patients (2/4). In this study, the characteristic of the case, improved a symptom after RT, was that tumor diameter is relatively large (Pt2: 78 mm, Pt8: 95 mm). Generally, the reduction of the physical pressure due to the tumor reduction is considered as a palliation mechanism. In addition to this, the improvement of secretion symptom by the reduction in quantity of the hormone due to the tumor reduction is considered as one of the mechanism in functional pNETs. Especially, the direct hormone symptom such as diarrhea, hypertension and hyperpigmentation may be relatively easy to improve. Whereas, the improvement of symptoms such as the stomachache by the physical pressure in Patient 11 may be hard to be obtained because the tumor cannot be eliminated. In Patient 7, symptoms may progress because nausea was not the direct hormone symptom by gastrin. The number of patients was too small for a comparison of efficacy (PFS and OS) between NET-G2 tumors and NECs, and the results of this study are therefore difficult to evaluate by themselves. However, our comparison of OS for patients with NET-G2 tumors and NECs did find that OS was 55.2 months for patients with NET-G2 tumors and 35.9 months for patients with NECs, with NECs having a poorer long-term prognosis, suggesting that although RT should be considered for palliative purposes, the indications for RT with the objective of prolonging life should be considered with more caution. This difference in outcome might also affect differences in the therapeutic efficacy of post-treatment. Metastasis to other organs was an aggravating factor in the clinical course of many patients with NECs, and RT might therefore be a more effective means of treatment for locally advanced cases or when metastasis to other organs is well-controlled prior to RT.
In terms of the toxicity of RT for primary pancreatic tumors, reported acute complications include sepsis secondary to gastric perforation and colitis, whereas late-onset radiation damage includes duodenal stenosis as well as gastrointestinal hemorrhage or perforation (16). The Grade 3 or worse adverse events observed in this study consisted of loss of appetite, diarrhea, and gastric hemorrhage; however, all of these were tolerable side effects and we must also consider that these may be symptoms of the functioning pNETs. The damage to the gastrointestinal tract, as it is the adjacent organ, requires particular care, and given that development of side effects might be delayed, the long-term outcomes in patients must be monitored.
This was a retrospective study that was also limited by the small number of patients and no control group, and we were thus unable to draw any conclusions about the efficacy of RT for PFS or OS. However, these results showed that no obvious growth of the primary pancreatic tumor was observed in any patient at the time of analysis and local control was therefore good for any histopathological types. In some cases, it provided a palliative effect, suggesting that RT could be considered as one of the multimodality treatments for pNETs. Prospective studies with larger numbers of patients are needed to clarify the clinical significance of RT for pNETs in the future.
Conclusion
RT to the primary site in patients with pNETs led to good disease control of local pancreatic tumors. However, the possibility that symptoms might worsen owing to metastases to organs outside the field of exposure must be considered, suggesting that it might be better to use RT to treat locally advanced cases or patients in whom distant metastases have been controlled.
